^
Association details:
| Biomarker: | NRAS mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Vectibix (panitumumab) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Excerpt:
Vectibix is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC)....Vectibix is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.
Source:
Excerpt:
The panel therefore strongly recommends RAS (KRAS/NRAS) genotyping of tumor tissue (either primary tumor or metastasis) in all patients with mCRC. Patients with known KRAS or NRAS mutations should not be treated with either cetuximab or panitumumab, either alone or in combination with other anticancer agents, because they have virtually no chance of benefit and the exposure to toxicity and expense cannot be justified.
Source:
Title:
Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer
Excerpt:
...Mutation status of KRAS gene`Mutation status of NRAS gene`Next generation sequencing performed on plasma cell-free DNA.`...
Trial ID:
Source:
Title:
Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer
Excerpt:
...- Wild-type KRAS (without mutation in exon 2 [codons 12 and 13], exon 3 [codons 59 and 61], and exon 4 [codons 117 and 146]) and wild-type NRAS (without mutation in exon 2 [codons 12 and 13], exon 3 [codons 59 and 61], and exon 4 [codons 117 and 146]) tumor status....
Trial ID:
More C2 evidence
Source:
Title:
FOLFOXIRI plus Panitumumab or FOLFOX plus Panitumumab in the treatment of metastatic colorectal cancer. folfoxiri più panitumumab contro folfox più panitumumab nel carcinoma del colonretto metastatico.
Excerpt:
...Tumore del colon-retto metastatico inizialmente non resecabile non precedentemente trattato per la malattia metastatica.Almeno una lesione misurabile in base ai criteri RECIST1.1.Disponibilità del campione tumorale (primitivo e/o metastasi).Una precedente chemioterapia adiuvante con fluoropirimidine in monoterapia è permessa se sono trascorsi almeno 6 mesi tra la fine dell’adiuvante e la prima recidiva.Stato di RAS (codoni 12, 13, 59, 61, 117 e 146 dei geni KRAS e NRAS) e BRAF (mutazione V600E) non mutato del tumore primitivo o delle metastasi....
Trial ID:
Source:
Title:
Optimal anti-EGFR Treatment of mCRC Patients with Low-Frequency RAS Mutation
Excerpt:
...• Histologically confirmed, UICC stage IV metastatic adenocarcinoma of the colon or rectum • Primarily non-resectable metastases or surgical resection refused by the patient • Documented RAS mutation determined by the local pathology • Low level RAS mutation in the tumor (KRAS and NRAS exon 2, 3, 4) with frequency of RAS mutation ≤ 20 % according to the central or local molecular pathology report. ...
Trial ID:
